Back to search
FDAFDA · Food and drugs·Recall number Z-2937-2026

ProNephro AKI (NGAL) Reagent Kit (100 tests). IVD Acute Kidney Injury Test System.

Published August 19, 2026 · Recall initiated: May 18, 2026

Summary

FDA records medical device Class II recall Z-2937-2026, published August 19, 2026 and initiated May 18, 2026. Recalling firm: Bioporto Diagnostics A/S; Status: Ongoing; Reported quantity: 400 units; Lot: Model number: ST101UB / 08787174 190; GTIN code: 5711435000156; Lot-number: 04909125 and 04912125. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The use of a non-validated rework process for assay reagents which could lead to missed diagnosis of renal disease, inappropriate treatment decisions, or inappropriate monitoring of renal disease in intended users.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Bioporto Diagnostics A/S
Distributor
Worldwide - The affected product distribution included the United States and the countries of European Union, Chile, and Hong Kong. No affected product was distributed to Canada; however, Health Canada was notified because the product is registered in Canada.
Lot
Model number: ST101UB / 08787174 190; GTIN code: 5711435000156; Lot-number: 04909125 and 04912125.
Risk classification
Class II
Area (FDA)
device
Country
Denmark

Related recalls

Questions about this recall

Was ProNephro AKI (NGAL) Reagent Kit (100 tests). IVD Acute Kidney Injury Test System. recalled?

Yes. FDA published recall Z-2937-2026 on August 19, 2026. Reported hazard: The use of a non-validated rework process for assay reagents which could lead to missed diagnosis of renal disease, inappropriate treatment decisions, or inappropriate monitoring of renal disease in intended users.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail